Pathogenesis of peroxisomal deficiency disorders (Zellweger syndrome) may be mediated by misregulation of the GABAergic system via the diazepam binding inhibitor

BMC Pediatrics

Volumn 4, Issue , 2004, Pages

  Breitling, Rainier ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; BENZODIAZEPINE; BINDING PROTEIN; DIAZEPAM BINDING INHIBITOR; DNA; LIPID; NEUROPEPTIDE Y RECEPTOR ANTAGONIST;

ARTICLE; BRAIN FUNCTION; CHILD; CRANIOFACIAL MALFORMATION; DISEASE MODEL; DISEASE SEVERITY; DISORDERS OF PEROXISOMAL FUNCTIONS; DNA MICROARRAY; GABAERGIC SYSTEM; HUMAN; LIFE EXPECTANCY; LIPID METABOLISM; MALFORMATION SYNDROME; MOUSE; MUSCLE HYPOTONIA; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PREGNANCY; SEIZURE; SIGNAL TRANSDUCTION; ZELLWEGER SYNDROME;

ANIMALS; DIAZEPAM BINDING INHIBITOR; DISEASE MODELS, ANIMAL; GABA-A RECEPTOR ANTAGONISTS; HUMANS; LIPID METABOLISM; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR CROSS-TALK; RECEPTORS, GABA-A; SIGNAL TRANSDUCTION; ZELLWEGER SYNDROME;

EID: 2642527881     PISSN: 14712431     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2431-4-5     Document Type: Article

References (74)

1. Baumgartner Matthias R., Saudubray Jean Marie: Peroxisomal disorders. Seminars in Neonatology 2002, 7:85-94.
2. Gould SJ, Raymond GV, Valle D: The peroxisome biogenesis disorders. The metabolic & molecular bases of inherited disease Volume 3. 8thth edition. Edited by: Scriver C R, Beaudet A L, Valle D and Sly W S. New York, McGraw-Hill; 2001:3181-3217.
3. Sacksteder KA, Gould SJ: The genetics of peroxisome biogenesis. Annu Rev Genet 2000, 34:623-652.
4. Powers JM, Moser HW: Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol 1998, 8:101-120.
5. Martinez M, Vazquez E, Garcia-Silva MT, Manzanares J, Bertran JM, Castello F, Mougan I: Therapeutic effects of docosahexaenoic acid ethyl ester in patients with generalized peroxisomal disorders. Am J Clin Nutr 2000, 71:376S-85S.
6. Mayatepek E, Lehmann WD, Fauler J, Tsikas D, Frolich JC, Schutgens RB, Wanders RJ, Keppler D: Impaired degradation of leukotrienes in patients with peroxisome deficiency disorders. J Clin Invest 1993, 91:881-888.
7. Jedlitschky G, Mayatepek E, Keppler D: Peroxisomal leukotriene degradation: biochemical and clinical implications. Adv Enzyme Regul 1993, 33:181-194.
8. Gressens P, Baes M, Leroux P, Lombet A, Van Veldhoven P, Janssen A, Vamecq J, Marret S, Evrard P: Neuronal migration disorder in Zellweger mice is secondary to glutamate receptor dysfunction. Ann Neurol 2000, 48:336-343.
9. Wanders RJA, Barth PG, Heymanns HS: Single peroxisomal enzyme deficiencies. The metabolic & molecular bases of inherited disease Volume 3. Edited by: Scriver C R, Beaudet A L, Valle D and Sly W S. New York, McGraw-Hill; 2001:3219-3256.
10. Faust PL, Hatten ME: Targeted deletion of the PEX2 peroxisome assembly gene in mice provides a model for Zellweger syndrome, a human neuronal migration disorder. J Cell Biol 1997, 139:1293-1305.
11. Baes M, Gressens P, Baumgart E, Carmeliet P, Casteels M, Fransen M, Evrard P, Fahimi D, Declercq PE, Collen D, van Veldhoven PP, Mannaerts GP: A mouse model for Zellweger syndrome. Nat Genet 1997, 17:49-57.
12. Li X, Baumgart E, Morrell JC, Jimenez-Sanchez G, Valle D, Gould SJ: PEX11 beta deficiency is lethal and impairs neuronal migration but does not abrogate peroxisome function. Mol Cell Biol 2002, 22:4358-4365.
13. Li X, Baumgart E, Dong GX, Morrell JC, Jimenez-Sanchez G, Valle D, Smith KD, Gould SJ: PEX11alpha is required for peroxisome proliferation in response to 4-phenylbutyrate but is dispensable for peroxisome proliferator-activated receptor alpha-mediated peroxisome proliferation. Mol Cell Biol 2002, 22:8226-8240.
14. Infante JP, Huszagh VA: Zellweger syndrome knockout mouse models challenge putative peroxisomal beta-oxidation involvement in docosahexaenoic acid (22:6n-3) biosynthesis. Mol Genet Metab 2001, 72:1-7.
15. Janssen A, Baes M, Gressens P, Mannaerts GP, Declercq P, Van Veldhoven PP: Docosahexaenoic acid deficit is not a major pathogenic factor in peroxisome-deficient mice. Lab Invest 2000, 80:31-35.
16. Vanhorebeek I, Baes M, Declercq PE: Isoprenoid biosynthesis is not compromised in a Zellweger syndrome mouse model. Biochim Biophys Acta 2001, 1532:28-36.
17. Janssen A, Gressens P, Grabenbauer M, Baumgart E, Schad A, Vanhorebeek I, Brouwers A, Declercq PE, Fahimi D, Evrard P, Schoonjans L, Collen D, Carmeliet P, Mannaerts G, Van Veldhoven P, Baes M: Neuronal migration depends on intact peroxisomal function in brain and in extraneuronal tissues. J Neurosci 2003, 23:9732-9741.
18. Baes M, Gressens P, Huyghe S, De NK, Qi C, Jia Y, Mannaerts GP, Evrard P, Van VP, Declercq PE, Reddy JK: The neuronal migration defect in mice with Zellweger syndrome (Pex5 knockout) is not caused by the inactivity of peroxisomal beta-oxidation. J Neuropathol Exp Neurol 2002, 61:368-374.
19. Baes M, Huyghe S, Carmeliet P, Declercq PE, Collen D, Mannaerts GP, Van Veldhoven PP: Inactivation of the peroxisomal multifunctional protein-2 in mice impedes the degradation of not only 2-methyl-branched fatty acids and bile acid intermediates but also of very long chain fatty acids. J Biol Chem 2000, 275:16329-16336.
20. Breitling R, Sharif O, Hartman ML, Krisans SK: Loss of compartmentalization causes misregulation of lysine biosynthesis in peroxisome-deficient yeast cells. Eukaryot Cell 2002, 1:978-986.
21. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson H. F., Jr., Hampton GM: Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001, 61:7388-7393.
22. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO: Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 2002, 99:12877-12882.
23. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S: Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia 2002, 4:337-346.
24. Costa E, Guidotti A: Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. Life Sci 1991, 49:325-344.
25. Knudsen J, Mandrup S, Rasmussen JT, Andreasen PH, Poulsen F, Kristiansen K: The function of acyl-CoA-binding protein (ACBP)/diazepam binding inhibitor (DBI). Mol Cell Biochem 1993, 123:129-138.
26. Bürgi B, Lichtensteiger W, Lauber ME, Schlumpf M: Ontogeny of diazepam binding inhibitor/acyl-CoA binding protein mRNA and peripheral benzodiazepine receptor mRNA expression in the rat. J Neuroendocrinol 1999, 11:85-100.
27. Bovolin P, Schlichting J, Miyata M, Ferrarese C, Guidotti A, Alho H: Distribution and characterization of diazepam binding inhibitor (DBI) in peripheral tissues of rat. Regul Pept 1990, 29:267-281.
28. Alho H, Harjuntausta T, Schultz R, Pelto-Huikko M, Bovolin P: Immunohistochemistry of diazepam binding inhibitor (DBI) in the central nervous system and peripheral organs: its possible role as an endogenous regulator of different types of benzodiazepine receptors. Neuropharmacology 1991, 30:1381-1386.
29. Alho H, Fremeau R. T., Jr., Tiedge H, Wilcox J, Bovolin P, Brosius J, Roberts JL, Costa E: Diazepam binding inhibitor gene expression: location in brain and peripheral tissues of rat. Proc Natl Acad Sci U S A 1988, 85:7018-7022.
30. Kolmer M, Rovio A, Alho H: The characterization of two diazepam binding inhibitor (DBI) transcripts in humans. Biochem J 1995, 306 ( Pt 2):327-330.
31. Mocchetti I, Santi MR: Diazepam binding inhibitor peptide: cloning and gene expression. Neuropharmacology 1991, 30:1365-1371.
32. Owens GP, Sinha AK, Sikela JM, Hahn WE: Sequence and expression of the murine diazepam binding inhibitor. Brain Res Mol Brain Res 1989, 6:101-108.
33. Guarneri P, Berkovich A, Guidotti A, Costa E: A study of diazepam binding inhibitor (DBI) processing products in human cerebrospinal fluid and in postmortem human brain. Neuropharmacology 1990, 29:419-428.
34. Ferrarese C, Cogliati T, Tortorella R, Zucca C, Bogliun G, Beghi E, Passoni D, Zoia C, Begni B, Airoldi L, Alho H, Frattola L: Diazepam binding inhibitor (DBI) in the plasma of pediatric and adult epileptic patients. Epilepsy Res 1998, 29:129-134.
35. Edgar PF, Schonberger SJ, Dean B, Faull RL, Kydd R, Cooper GJ: A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals. Mol Psychiatry 1999, 4:173-178.
36. Papadopoulos V, Berkovich A, Krueger KE, Costa E, Guidotti A: Diazepam binding inhibitor and its processing products stimulate mitochondrial steroid biosynthesis via an interaction with mitochondrial benzodiazepine receptors. Endocrinology 1991, 129:1481-1488.
37. Cavallaro S, Korneyev A, Guidotti A, Costa E: Diazepam-binding inhibitor (DBI)-processing products, acting at the mitochondrial DBI receptor, mediate adrenocorticotropic hormoneinduced steroidogenesis in rat adrenal gland. Proc Natl Acad Sci U S A 1992, 89:10598-10602.
38. Boujrad N, Hudson J. R., Jr., Papadopoulos V: Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor. Proc Natl Acad Sci U S A 1993, 90:5728-5731.
39. Cosentino M, Marino F, Cattaneo S, Di Grazia L, Francioli C, Fietta AM, Lecchini S, Frigo G: Diazepam-binding inhibitor-derived peptides induce intracellular calcium changes and modulate human neutrophil function. J Leukoc Biol 2000, 67:637-643.
40. Gandolfo P, Patte C, Leprince J, Thoumas JL, Vaudry H, Tonon MC: The stimulatory effect of the octadecaneuropeptide (ODN) on cytosolic Ca2+ in rat astrocytes is not mediated through classical benzodiazepine receptors. Eur J Pharmacol 1997, 322:275-281.
41. Rosendal J, Ertbjerg P, Knudsen J: Characterization of ligand binding to acyl-CoA-binding protein. Biochem J 1993, 290 ( Pt 2):321-326.
42. Knudsen J, Neergaard TB, Gaigg B, Jensen MV, Hansen JK: Role of acyl-CoA binding protein in acyl-CoA metabolism and acyl-CoA-mediated cell signaling. J Nutr 2000, 130:294S-298S.
43. Helledie T, Grontved L, Jensen SS, Kiilerich P, Rietveld L, Albrektsen T, Boysen MS, Nohr J, Larsen LK, Fleckner J, Stunnenberg HG, Kristiansen K, Mandrup S: The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents. J Biol Chem 2002, 277:26821-26830.
44. Swinnen JV, Alen P, Heyns W, Verhoeven G: Identification of diazepam-binding Inhibitor/Acyl-CoA-binding protein as a sterol regulatory element-binding protein-responsive gene. J Biol Chem 1998, 273:19938-19944.
45. Borboni P, Condorelli L, De Stefanis P, Sesti G, Lauro R: Modulation of insulin secretion by diazepam binding inhibitor and its processing products. Neuropharmacology 1991, 30:1399-1403.
46. Ostenson CG, Ahren B, Karlsson S, Sandberg E, Efendic S: Effects of porcine diazepam-binding inhibitor on insulin and glucagon secretion in vitro from the rat endocrine pancreas. Regul Pept 1990, 29:143-151.
47. Laegreid L, Olegard R, Wahlstrom J, Conradi N: Abnormalities in children exposed to benzodiazepines in utero. Lancet 1987, 1:108-109.
48. Laegreid L, Olegard R, Walstrom J, Conradi N: Teratogenic effects of benzodiazepine use during pregnancy. J Pediatr 1989, 114:126-131.
49. Laegreid L, Olegard R, Conradi N, Hagberg G, Wahlstrom J, Abrahamsson L: Congenital malformations and maternal consumption of benzodiazepines: a case-control study. Dev Med Child Neurol 1990, 32:432-441.
50. Laegreid L, Olegard R, Wahlstrom J, Conradi N, Sisfontes L: Benzodiazepine overconsumption in pregnancy. Lancet 1987, 2:1405-1406.
51. Winter RM: In utero Exposure to Benzodiazepines. Lancet 1987, 1:627-627.
52. Iqbal MM, Sobhan T, Ryals T: Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002, 53:39-49.
53. Katz RA: Effect of diazepam on the embryonic development of the palate in the rat. J Craniofac Genet Dev Biol 1988, 8:155-166.
54. Tocco DR, Renskers K, Zimmerman EF: Diazepam-induced cleft palate in the mouse and lack of correlation with the H-2 locus. Teratology 1987, 35:439-445.
55. Zimmerman EF: Role of neurotransmitters in palate development and teratologic implications. Prog Clin Biol Res 1985, 171:283-294.
56. Tucker JC: Benzodiazepines and the developing rat: a critical review. Neurosci Biobehav Rev 1985, 9:101-111.
57. Condie BG, Bain G, Gottlieb DI, Capecchi MR: Cleft palate in mice with a targeted mutation in the gamma-aminobutyric acid-producing enzyme glutamic acid decarboxylase 67. Proc Natl Acad Sci U S A 1997, 94:11451-11455.
58. Culiat CT, Stubbs LJ, Woychik RP, Russell LB, Johnson DK, Rinchik EM: Deficiency of the beta 3 subunit of the type A gamma-aminobutyric acid receptor causes cleft palate in mice. Nat Genet 1995, 11:344-346.
59. Guidotti A, Forchetti CM, Corda MG, Konkel D, Bennett CD, Costa E: Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci U S A 1983, 80:3531-3535.
60. Schousboe A: Pharmacologic and therapeutic aspects of the developmentally regulated expression of GABA(A) and GABA(B) receptors: cerebellar granule cells as a model system. Neurochem Int 1999, 34:373-377.
61. Paladini CA, Iribe Y, Tepper JM: GABAA receptor stimulation blocks NMDA-induced bursting of dopaminergic neurons in vitro by decreasing input resistance. Brain Res 1999, 832:145-151.
62. Katsura M, Takesue M, Shuto K, Mohri Y, Tarumi C, Tsujimura A, Shirotani K, Ohkuma S: NMDA receptor activation enhances diazepam binding inhibitor and its mRNA expressions in mouse cerebral cortical neurons. Brain Res Mol Brain Res 2001, 88:161-165.
63. Lamacz M, Tonon MC, Smih-Rouet F, Patte C, Gasque P, Fontaine M, Vaudry H: The endogenous benzodiazepine receptor ligand ODN increases cytosolic calcium in cultured rat astrocytes. Brain Res Mol Brain Res 1996, 37:290-296.
64. Ferrarese C, Vaccarino F, Alho H, Mellstrom B, Costa E, Guidotti A: Subcellular location and neuronal release of diazepam binding inhibitor. J Neurochem 1987, 48:1093-1102.
65. Patte C, Gandolfo P, Leprince J, Thoumas JL, Fontaine M, Vaudry H, Tonon MC: GABA inhibits endozepine release from cultured rat astrocytes. Glia 1999, 25:404-411.
66. De Stefanis P, Impagnatiello F, Berkovich A, Guidotti A: Inhibitory effect of ODN, a naturally occurring processing product of diazepam binding inhibitor, on secretagogues-induced insulin secretion. Regul Pept 1995, 56:153-165.
67. De Zeeuw CI, Van Alphen AM, Hawkins RK, Ruigrok TJ: Climbing fibre collaterals contact neurons in the cerebellar nuclei that provide a GABAergic feedback to the inferior olive. Neuroscience 1997, 80:981-986.
68. Gabbott PL, Somogyi J, Stewart MG, Hamori J: GABA-immunoreactive neurons in the rat cerebellum: a light and electron microscope study. J Comp Neurol 1986, 251:474-490.
69. Aoki E, Semba R, Kashiwamata S: When does GABA-like immunoreactivity appear in the rat cerebellar GABAergic neurons? Brain Res 1989, 502:245-251.
70. Xu W, Cormier R, Fu T, Covey DF, Isenberg KE, Zorumski CF, Mennerick S: Slow death of postnatal hippocampal neurons by GABA(A) receptor overactivation. J Neurosci 2000, 20:3147-3156.
71. Ikonomidou C, Bittigau P, Ishimaru MJ, Wozniak DF, Koch C, Genz K, Price MT, Stefovska V, Horster F, Tenkova T, Dikranian K, Olney JW: Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 2000, 287:1056-1060.
72. Cherubini E, Gaiarsa JL, Ben-Ari Y: GABA: an excitatory transmitter in early postnatal life. Trends Neurosci 1991, 14:515-519.
73. Leinekugel X, Khalilov I, McLean H, Caillard O, Gaiarsa JL, Ben-Ari Y, Khazipov R: GABA is the principal fast-acting excitatory transmitter in the neonatal brain. Adv Neurol 1999, 79:189-201.
74. Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G: GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience 2000, 101:815-850.